Structural Modifications of Thalidomide Produce Analogs with Enhanced Tumor Necrosis Factor Inhibitory Activity

Muller G., 1995, Novel inhibitors of tumor necrosis factor-α. Presented in part at the 210th American Chemical Society National Meeting

Schumacher H., 1965, Brit. J. Pharmacol., 25, 324

Georgopoulos A., 1990, Int. J. Exp. Clin. Chemother., 3, 141

D'Arcy P. F., 1994, Adverse Drug React. Toxicol. Rev., 13, 76

Sheskin J, 1965, Clin. Pharmacol. Ther., 6, 303, 10.1002/cpt196563303

Hendler S. S., 1983, Med. Hypotheses, 10, 443, 10.1016/0306-9877(83)90009-9

Crawford C. L, 1994, Adverse Drug React. Toxicol. Rev., 13, 192

Gutierrez-Rodriguez O., 1984, Arthritis Rheum., 27, 1121, 10.1002/art.1780271006

Peterson D. L., 1995, Infection Clin. Infect. Dis., 20, 254

Schuler U., 1995, Drug Safety, 12, 369, 10.2165/00002018-199512060-00002

Vogelsang G. B., 1987, Trans. Proc., 2661

Klausner J., 1996, J. Acquired Immune Defic. Syndr., 11, 257

Crawford C. L., 1969, Lepr. Rev., 40, 128

Smithells R. W., 1992, J. Med. Genet., 29, 723, 10.1136/jmg.29.10.716

Sampaio E. P., 1991, J. Exp. Med., 173, 703, 10.1084/jem.173.3.699

Koch H. P, 1985, Prog. Med. Chem., 22, 242

Gunzler V., 1989, Med. Hypotheses, 30, 109, 10.1016/0306-9877(89)90094-7

D'amato R. J., 1994, Proc. Natl. Acad. Sci. U.S.A., 91, 4085

Kalvin D., 1985, J. Org. Chem., 50, 2263, 10.1021/jo00213a012

Madigan D., 1989, Aug. 23

Shealy Y. F., 1968, J. Pharm. Sci., 57, 764, 10.1002/jps.2600570508

Davies S. G., 1991, Tetrahedron Asymmetry, 2, 183, 10.1016/S0957-4166(00)82354-X

Assay, Piscataway, NJ) density centrifugation. Cells (106 cells/mL) were cultured in RPMI (Gibco Laboratories

Thalidomide, All other IC50's were calculated by nonlinear regression analysis (variable slope) using Prism by GraphPad Software

Wintersk W., 1992, Lancet, 339, 365, 10.1016/0140-6736(92)91684-Z

Eriksson T., 1995, Chirality, 7, 52, 10.1002/chir.530070109

Reepmeyer J, 1996, Chirality, 8, 17, 10.1002/(SICI)1520-636X(1996)8:1<11::AID-CHIR4>3.0.CO;2-J